Where is Gubra located?

Gubra is headquartered in Horsholm, Denmark.

How many employees does Gubra have?

As of Jul 31, 2026, the latest employee count at Gubra is 327.

Where does Gubra rank among its competitors?

Gubra ranks 1st amongst 227 active competitors, of which 12 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was RxCelerate, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of Gubra?

Gubra's top competitors include Yashraj Biotechnology, BioQual and Gentronix. Among them, RxCelerate secured the most recent funding round in February, 2024.

Gubra - 2026 Company Profile, Team, Competitors & Financials

Gubra is a public company based in Horsholm (Denmark), founded in 2008 by Niels Vrang. It operates as a Preclinical CRO focussed on developing treatments for NAFLD/NASH, diabetes, and obesity. The company has 227 active competitors, including 12 funded and 42 that have exited. Its top competitors include companies like Yashraj Biotechnology, BioQual and Gentronix.

Company Details

Gubra is a preclinical CRO offering its services for developing drugs and treatments for NAFLD/NASH, Diabetes and Obesity. The company's service portfolio includes In Vivo Pharmacology, Histology And Stereology, Molecular Biology, and Assays. The company has in vivo models such as diet-induced obese mouse models, accelerated diet-induced obese mouse models, ob/ob or obese models, db/db models, Male ZDF (Zucker Diabetic Fatty) rats, for studying efficacy, Mechanism of Action and Metabolic Phenotyping studies and for establishing Proof of Concept. Their Histology and Stereology services include Histochemical Staining, Immunohistochemistry (single/double/triple labeling), Pancreas biology, gut morphometry, liver pathology Unbiased quantitative analyses and CNS Stereology.

Website: gubra.dk
Email ID: *****@gubra.dk

Key Metrics

Founded Year

2008

Location

Horsholm, Denmark

Stage

Public

Ranked

1^st among 227 active competitors

Employee Count

327 as on Jul 31, 2026

Investment & Acquisitions

MiniGut

Similar Companies

Yashraj Biotechnology & 275 more

Exit Details

Public

View Gubra's full profile

Gubra is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Gubra A/s CIN: 30514041 , Denmark, Active	Oct 08, 2008	-	-

Gubra got listed on Apr 05, 2023.

Click here to take a look at Gubra's IPO in detail

Gubra has not raised any funding rounds yet.

The founders of Gubra is Niels Vrang.

Here are the details of Gubra's key team members:

Niels Vrang: Co-Founder & Chairman of Gubra.
Henrik Blou: CEO of Gubra.

View details of Gubra's Founder profiles and Board Members

Gubra's employee count trend

Gubra has 327 employees as of Jul 26. Here is Gubra's employee count trend over the years:

Uncover Gubra's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gubra include Yashraj Biotechnology, BioQual and Gentronix. Here is the list of Top 10 competitors of Gubra, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Gubra 2008, Horsholm (Denmark), Public	Preclinical CRO focussed on developing treatments for NAFLD/NASH, diabetes, and obesity	-	-	49/100
2nd	Yashraj Biotechnology 1999, Mumbai (India), Early Stage	Provider of recombinant antigens and antibodies for diagnostic and research	$492K	Supreme Industries, CFM & 4 others	49/100
3rd	BioQual 1981, Rockville (United States), Public	Integrated CRO focused on infectious diseases	-	-	48/100
4th	Gentronix 1999, Alderley Edge (United Kingdom), Acquired	Providr of in-vitro and in-vivo genetic toxicology screening services	$3.84M	NVM, Mercia	47/100
5th	RxCelerate 2012, Babraham (United Kingdom), Seed	Provider of pre-clinical contract research services	-	Total Medical Ventures	41/100
6th	GV Research Platform 2020, Hyderabad (India), Funding Raised	Provides platform for conducting research and drug development services	-	JV Ventures	41/100
7th	ReveraGen 2008, Rockville (United States), Funding Raised	Developer of steroids for treating Duchenne muscular dystrophy	-	FDA, NINDS & 10 others	41/100
8th	Absorption 1996, Exton (United States), Acquired	Premier life science service provider offering comprehensive R&D and manufacturing solutions	-	-	41/100
9th	Shanghai Semero Biotechnology 2014, Shanghai (China), Series C	Provider of diversified preclinical services for brain-related disorders	$20.8M	GF Xinde Investment Management, Tianrui Fengnian Private Equity Fund ... & 8 others	41/100
10th	Tigermed 2004, Hangzhou (China), Public	Provider of drug development and pre clinical services	-	CDG Capital, Qiming Venture Partners	40/100